Indications
Neratinib Maleate is a kinase inhibitor. It is used on its own as extended adjuvant treatment for adult patients with early-stage HER2-positive breast cancer, after they have finished adjuvant Trastuzumab based therapy. It is also given together with Capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer. These are patients who have already received two or more anti-HER2 based regimens in the metastatic setting.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Neratinib is a kinase inhibitor. It binds irreversibly to Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2) and HER4. Chemically, neratinib belongs to the 4-anilino quinolidine class of protein kinase inhibitors.
Pregnancy & Breastfeeding
Neratinib can harm an unborn baby when it is given to a pregnant woman, so pregnant women should be told about this risk to the baby. There is no data on whether Neratinib or its metabolites pass into human milk, or on what they might do to a breastfed infant or to milk production. Men and women who could have children should be advised to use effective contraception while they are taking Neratinib and for at least 1 month after the last dose.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.